Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved]
Syndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic arthritis (PAPASH), spondyloarthritis (PASS) and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2021-07-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/10-381/v2 |
| _version_ | 1819242818836627456 |
|---|---|
| author | Georgios Nikolakis Katja Kreibich Aristeidis Vaiopoulos Katarzyna Kaleta Joud Talas Markus Becker Christos C. Zouboulis |
| author_facet | Georgios Nikolakis Katja Kreibich Aristeidis Vaiopoulos Katarzyna Kaleta Joud Talas Markus Becker Christos C. Zouboulis |
| author_sort | Georgios Nikolakis |
| collection | DOAJ |
| description | Syndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic arthritis (PAPASH), spondyloarthritis (PASS) and psoriatic arthritis (PsAPASH) and are categorized in the autoinflammatory syndromes. Anti-TNF-α and anti-IL-1a blockade are between the therapeutic approaches that improve skin symptoms and prevent permanent osteoarticular damage. This case report refers to the successful treatment of a mixed phenotype of the aforementioned symptoms using the IL-17A inhibitor secukinumab after initial treatment with adalimumab. The therapy improved both cutaneous and reported osteoarticular symptoms. Different approaches for these recalcitrant HS syndromes are essential in order to achieve long-term remission for those patients. |
| first_indexed | 2024-12-23T14:45:51Z |
| format | Article |
| id | doaj.art-d04a23420f5f4ba4b917411dc251d51b |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-23T14:45:51Z |
| publishDate | 2021-07-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-d04a23420f5f4ba4b917411dc251d51b2022-12-21T17:43:05ZengF1000 Research LtdF1000Research2046-14022021-07-011010.12688/f1000research.52100.257760Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved]Georgios Nikolakis0Katja Kreibich1Aristeidis Vaiopoulos2Katarzyna Kaleta3Joud Talas4Markus Becker5Christos C. Zouboulis6Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, 06847, GermanyDepartments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, 06847, GermanyDepartments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, 06847, GermanyDepartment of Dermatology, Jagiellonian University Medical College, Krakow, 31-008, PolandDepartments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, 06847, GermanyDepartments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, 06847, GermanyDepartments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, 06847, GermanySyndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic arthritis (PAPASH), spondyloarthritis (PASS) and psoriatic arthritis (PsAPASH) and are categorized in the autoinflammatory syndromes. Anti-TNF-α and anti-IL-1a blockade are between the therapeutic approaches that improve skin symptoms and prevent permanent osteoarticular damage. This case report refers to the successful treatment of a mixed phenotype of the aforementioned symptoms using the IL-17A inhibitor secukinumab after initial treatment with adalimumab. The therapy improved both cutaneous and reported osteoarticular symptoms. Different approaches for these recalcitrant HS syndromes are essential in order to achieve long-term remission for those patients.https://f1000research.com/articles/10-381/v2 |
| spellingShingle | Georgios Nikolakis Katja Kreibich Aristeidis Vaiopoulos Katarzyna Kaleta Joud Talas Markus Becker Christos C. Zouboulis Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved] F1000Research |
| title | Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved] |
| title_full | Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved] |
| title_fullStr | Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved] |
| title_full_unstemmed | Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved] |
| title_short | Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved] |
| title_sort | case report psapsash syndrome an alternative phenotype of syndromic hidradenitis suppurativa treated with the il 17a inhibitor secukinumab version 2 peer review 2 approved |
| url | https://f1000research.com/articles/10-381/v2 |
| work_keys_str_mv | AT georgiosnikolakis casereportpsapsashsyndromeanalternativephenotypeofsyndromichidradenitissuppurativatreatedwiththeil17ainhibitorsecukinumabversion2peerreview2approved AT katjakreibich casereportpsapsashsyndromeanalternativephenotypeofsyndromichidradenitissuppurativatreatedwiththeil17ainhibitorsecukinumabversion2peerreview2approved AT aristeidisvaiopoulos casereportpsapsashsyndromeanalternativephenotypeofsyndromichidradenitissuppurativatreatedwiththeil17ainhibitorsecukinumabversion2peerreview2approved AT katarzynakaleta casereportpsapsashsyndromeanalternativephenotypeofsyndromichidradenitissuppurativatreatedwiththeil17ainhibitorsecukinumabversion2peerreview2approved AT joudtalas casereportpsapsashsyndromeanalternativephenotypeofsyndromichidradenitissuppurativatreatedwiththeil17ainhibitorsecukinumabversion2peerreview2approved AT markusbecker casereportpsapsashsyndromeanalternativephenotypeofsyndromichidradenitissuppurativatreatedwiththeil17ainhibitorsecukinumabversion2peerreview2approved AT christosczouboulis casereportpsapsashsyndromeanalternativephenotypeofsyndromichidradenitissuppurativatreatedwiththeil17ainhibitorsecukinumabversion2peerreview2approved |